GENENTA SCIENCE SPA - ADR (GNTA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GNTA • US36870W1009

0.89 USD
-0.1 (-10.1%)
Last: Feb 3, 2026, 03:35 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GNTA. GNTA was compared to 524 industry peers in the Biotechnology industry. GNTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GNTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • GNTA had negative earnings in the past year.
  • GNTA had a negative operating cash flow in the past year.
  • In the past 5 years GNTA always reported negative net income.
  • In the past 5 years GNTA always reported negative operating cash flow.
GNTA Yearly Net Income VS EBIT VS OCF VS FCFGNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -40.37%, GNTA is in line with its industry, outperforming 58.97% of the companies in the same industry.
  • The Return On Equity of GNTA (-71.82%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -40.37%
ROE -71.82%
ROIC N/A
ROA(3y)-45.86%
ROA(5y)-36.67%
ROE(3y)-51.85%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
GNTA Yearly ROA, ROE, ROICGNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GNTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNTA Yearly Profit, Operating, Gross MarginsGNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

  • The number of shares outstanding for GNTA has been increased compared to 1 year ago.
  • Compared to 5 years ago, GNTA has more shares outstanding
  • There is no outstanding debt for GNTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GNTA Yearly Shares OutstandingGNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
GNTA Yearly Total Debt VS Total AssetsGNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • GNTA has an Altman-Z score of -2.89. This is a bad value and indicates that GNTA is not financially healthy and even has some risk of bankruptcy.
  • GNTA has a Altman-Z score (-2.89) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.62 indicates that GNTA is somewhat dependend on debt financing.
  • GNTA has a worse Debt to Equity ratio (0.62) than 70.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -2.89
ROIC/WACCN/A
WACCN/A
GNTA Yearly LT Debt VS Equity VS FCFGNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 13.20 indicates that GNTA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 13.20, GNTA belongs to the top of the industry, outperforming 89.31% of the companies in the same industry.
  • GNTA has a Quick Ratio of 13.20. This indicates that GNTA is financially healthy and has no problem in meeting its short term obligations.
  • GNTA has a better Quick ratio (13.20) than 89.31% of its industry peers.
Industry RankSector Rank
Current Ratio 13.2
Quick Ratio 13.2
GNTA Yearly Current Assets VS Current LiabilitesGNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 3.88% over the past year.
EPS 1Y (TTM)3.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • GNTA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.35% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.85%
EPS Next 2Y-5.25%
EPS Next 3Y-9.35%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNTA Yearly EPS VS EstimatesGNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • GNTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNTA Price Earnings VS Forward Price EarningsGNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNTA Per share dataGNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as GNTA's earnings are expected to decrease with -9.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.25%
EPS Next 3Y-9.35%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for GNTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GENENTA SCIENCE SPA - ADR

NASDAQ:GNTA (2/3/2026, 3:35:45 PM)

0.89

-0.1 (-10.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners10.03%
Inst Owner Change1.13%
Ins Owners26.27%
Ins Owner ChangeN/A
Market Cap20.85M
Revenue(TTM)N/A
Net Income(TTM)-8.70M
Analysts82.86
Price Target21.42 (2306.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.37%
ROE -71.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.86%
ROA(5y)-36.67%
ROE(3y)-51.85%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.2
Quick Ratio 13.2
Altman-Z -2.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)114.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.82%
EPS Next Y-13.85%
EPS Next 2Y-5.25%
EPS Next 3Y-9.35%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-141.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3YN/A
OCF growth 5YN/A

GENENTA SCIENCE SPA - ADR / GNTA FAQ

Can you provide the ChartMill fundamental rating for GENENTA SCIENCE SPA - ADR?

ChartMill assigns a fundamental rating of 1 / 10 to GNTA.


Can you provide the valuation status for GENENTA SCIENCE SPA - ADR?

ChartMill assigns a valuation rating of 0 / 10 to GENENTA SCIENCE SPA - ADR (GNTA). This can be considered as Overvalued.


Can you provide the profitability details for GENENTA SCIENCE SPA - ADR?

GENENTA SCIENCE SPA - ADR (GNTA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for GENENTA SCIENCE SPA - ADR?

The Earnings per Share (EPS) of GENENTA SCIENCE SPA - ADR (GNTA) is expected to decline by -13.85% in the next year.